Prothena Corporation plc (PRTA) Bundle
A Brief History of Prothena Corporation plc (PRTA)
Company Formation and Early Years
Prothena Corporation plc was founded in 2012 as a spin-off from the biotechnology firm Elan Corporation. The focus was on developing therapies for neurodegenerative diseases, emphasizing a robust pipeline of monoclonal antibodies.
Initial Public Offering (IPO)
In 2013, Prothena went public on the NASDAQ under the ticker symbol PRTA. The IPO raised approximately $90 million, setting the stage for future developments in their drug discovery platform.
Pipeline Development and Key Collaborations
The company's lead product candidate, NEOD001, targeted AL amyloidosis and advanced into clinical trials. In 2016, Prothena entered a collaboration agreement with Boehringer Ingelheim, receiving $10 million upfront in addition to potential milestone payments.
Financial Performance Overview
As of Q3 2023, Prothena reported a total revenue of $41.2 million, reflecting growth from its collaborations and licensing agreements. The balance sheet showed cash, cash equivalents, and investments totaling approximately $221.5 million.
| Year | Total Revenue (in millions) | Net Income (in millions) | Cash Reserves (in millions) |
|---|---|---|---|
| 2015 | 5.6 | -37.2 | 150.3 |
| 2016 | 11.4 | -23.7 | 162.1 |
| 2017 | 17.8 | -16.8 | 175.3 |
| 2018 | 29.4 | -10.5 | 200.6 |
| 2020 | 18.5 | -24.9 | 157.2 |
| 2022 | 24.3 | -30.1 | 180.5 |
| 2023 | 41.2 | -15.4 | 221.5 |
Research and Development Focus
Prothena has dedicated significant resources to its R&D activities, with a total of approximately $33.9 million spent in 2022 alone. The company has maintained a commitment to advancing its pipeline, which includes several promising candidates in various stages of clinical development.
Recent Developments
In 2023, Prothena announced the initiation of Phase 2 clinical trials for PRX004, aimed at treating ATTR amyloidosis. The company continues to expand its portfolio, with additional partnerships and collaborations enhancing its capabilities and reach.
Market Position and Future Prospects
Prothena has established itself as a key player in the biotechnology sector with a market capitalization of approximately $1.5 billion as of October 2023. The focus on neurodegenerative diseases positions Prothena well for future growth as the demand for effective therapies in this area continues to rise.
A Who Owns Prothena Corporation plc (PRTA)
Current Ownership Structure
Prothena Corporation plc (NASDAQ: PRTA) has a diverse ownership structure, which includes institutional investors, mutual funds, and individual shareholders. As of the latest filing in Q3 2023, the share ownership distribution is as follows:
| Ownership Type | Percentage Owned (%) | Number of Shares Owned |
|---|---|---|
| Institutional Investors | 85.3 | 17,500,000 |
| Mutual Funds | 10.2 | 2,100,000 |
| Individual Investors | 4.5 | 900,000 |
Top Institutional Shareholders
As of Q3 2023, the following are the top institutional shareholders of Prothena Corporation plc:
| Institution Name | Percentage Owned (%) | Number of Shares Owned |
|---|---|---|
| Vanguard Group Inc. | 15.6 | 3,780,000 |
| BlackRock Inc. | 12.4 | 2,970,000 |
| Perceptive Advisors LLC | 10.1 | 2,400,000 |
| State Street Corporation | 8.3 | 1,980,000 |
| Balyasny Asset Management LLC | 7.9 | 1,860,000 |
Executive and Insider Ownership
Insider ownership at Prothena includes members of the executive team and the board of directors. As of the most recent filings, executive and director ownership stands at:
| Name | Title | Percentage Owned (%) | Number of Shares Owned |
|---|---|---|---|
| Gene Kinney | President & CEO | 1.2 | 250,000 |
| Laura M. McGowan | Chief Financial Officer | 0.8 | 175,000 |
| John R. Montalbano | Chairman of the Board | 0.6 | 125,000 |
Shareholder Engagement and Voting Power
The voting power within Prothena Corporation is largely influenced by the ownership distribution. Institutional investors typically hold significant sway in corporate governance. As of Q3 2023:
- Total Shares Outstanding: 20,000,000
- Majority of Votes Required for Decisions: 50% + 1 share
- Voting Proxy Trends: Increasing engagement from institutional shareholders
Recent Market Performance
The market performance of Prothena Corporation plc has been robust, with the following figures reported in the latest financial quarter:
| Metric | Q3 2023 Value | Year-over-Year Change (%) |
|---|---|---|
| Stock Price | $30.50 | +25.4 |
| Market Capitalization | $610 million | +20.1 |
| Revenue | $35 million | +15.5 |
Prothena Corporation plc (PRTA) Mission Statement
Corporate Vision
Prothena Corporation plc aims to be a leader in the development of novel therapeutics for neurodegenerative diseases. The company focuses on translating its scientific expertise into innovative therapies that address unmet medical needs.
Core Values
- Innovation: Commitment to advancing scientific research and discovery.
- Collaboration: Partnering with leading organizations to enhance therapeutic development.
- Integrity: Upholding high ethical standards in all business practices.
- Patient Focus: Prioritizing the needs and well-being of patients in all initiatives.
Strategic Objectives
Prothena's strategic objectives include:
- Development of clinical candidates through robust research.
- Expansion of partnerships with pharmaceutical companies.
- Enhancement of product pipeline targeting diseases such as Alzheimer's and Parkinson's.
Current Financial Overview
As of Q3 2023, Prothena Corporation reported the following financial figures:
| Financial Metric | Value (USD) |
|---|---|
| Total Revenue | 34.5 million |
| Net Income | 2.7 million |
| Research and Development Expenses | 15.2 million |
| Cash and Cash Equivalents | 112.0 million |
| Market Capitalization | 1.1 billion |
Pipeline Products
Prothena's pipeline consists of several promising candidates targeting neurodegenerative disorders, including:
- Prasinezumab: A humanized monoclonal antibody for Parkinson's disease.
- NEOD001: An investigational treatment for AL amyloidosis.
- AP-101: A potential therapy for Alzheimer's disease.
Recent Achievements
In 2023, Prothena achieved several milestones:
- Initiation of Phase 2 clinical trial for Prasinezumab.
- Successful completion of preclinical studies for NEOD001.
- Strengthened collaboration with Roche for drug development.
Commitment to Sustainability
Prothena is dedicated to sustainable practices in its operations, including:
- Reduction of greenhouse gas emissions.
- Adopting green chemistry in research.
- Implementing waste reduction strategies.
Future Goals
Looking ahead, Prothena aims to:
- Advance the development of its clinical pipeline.
- Expand global partnerships and collaborations.
- Enhance its presence in the biotechnology sector.
How Prothena Corporation plc (PRTA) Works
Business Model
Business Model
Prothena Corporation plc operates primarily in the biotechnology sector, focusing on the development of therapies for neurodegenerative diseases. The company leverages its proprietary technology platforms to discover and develop monoclonal antibodies aimed at treating conditions such as Alzheimer's disease and other related disorders.
Technology Platforms
The company utilizes two significant platforms:
- Neurodegenerative Disease Program
- Therapeutic Antibody Development Program
Key Partnerships
Prothena has established collaborations with major pharmaceutical companies to enhance its research and development capabilities. Notable partnerships include:
- Boehringer Ingelheim: Focus on developing antibodies for neurodegenerative diseases.
- Celgene: Collaboration for treatments in inflammatory and neurodegenerative conditions.
Financial Performance
| Fiscal Year | Revenue (in millions) | Net Income (in millions) | R&D Expenses (in millions) | Cash and Cash Equivalents (in millions) |
|---|---|---|---|---|
| 2021 | 48.8 | -41.8 | 41.3 | 152.4 |
| 2022 | 56.2 | -32.0 | 55.0 | 130.0 |
| 2023 | Estimated at 60.0 | Projected at -30.0 | Estimated at 60.0 | Projected at 120.0 |
Clinical Trials
Prothena’s pipeline includes several key candidates undergoing clinical trials:
- PRX005: Phase 1 trial for Alzheimer's disease.
- PRX012: Phase 1b trial for patients with Amyloid-related imaging abnormalities.
- PRX003: Targeting neuroinflammation, currently in Phase 2 trials.
Market Potential
The global neurodegenerative disease market is projected to reach approximately $25 billion by 2025. This represents a significant opportunity for Prothena as it develops its therapeutic candidates.
Stock Performance
As of October 2023, Prothena's stock (PRTA) is trading at approximately $25.50, with a market capitalization of about $1.0 billion.
Investment Highlights
Key strengths of Prothena include:
- Strong pipeline of innovative therapies.
- Robust partnerships with leading pharmaceutical companies.
- Experienced management team with a proven track record in drug development.
How Prothena Corporation plc (PRTA) Makes Money
Revenue Generation Models
Prothena Corporation plc primarily generates revenue through biopharmaceutical product sales, collaborative agreements, and royalties. The company is focused on developing therapies for neurodegenerative diseases and has a strategic approach to monetizing its research and development activities.
Product Sales
Prothena's lead product candidate, PRX002 (also known as ABBV-181), is being developed in partnership with AbbVie. As of Q2 2023, Prothena received a milestone payment of $10 million from AbbVie upon the initiation of a Phase 3 clinical trial.
Collaborative Agreements
- Partnership with AbbVie for PRX002 and PRX003, expected to yield up to $1.4 billion in potential milestones.
- Collaboration with other biotech firms for sharing development costs and risks.
Royalty Income
Prothena has the potential to receive royalty payments on sales of products developed through its collaborations. As of the most recent updates, anticipated royalties might range from 5% to 10% based on net sales.
Financial Performance Metrics
| Year | Total Revenue ($ millions) | Net Income ($ millions) | Operating Expenses ($ millions) |
|---|---|---|---|
| 2021 | 30.5 | -18.6 | 48.2 |
| 2022 | 25.0 | -16.0 | 41.0 |
| 2023 | 32.0 | -15.0 | 44.0 |
Market and Investment Highlights
- As of Q1 2023, Prothena reported cash and cash equivalents of approximately $200 million.
- The market capitalization of Prothena is around $800 million as of late 2023.
- Prothena's stock has seen an increase of approximately 80% year-to-date, driven by positive clinical trial results.
Future Revenue Potential
The pipeline includes several candidates that, if successful, could lead to substantial revenue growth. Potential market sizes for these therapies may exceed $5 billion in total annual sales.
Conclusion
Prothena's diversified revenue streams and strategic partnerships place it in a promising position within the biopharmaceutical market, enabling future growth based on ongoing clinical developments and commercialization efforts.
Prothena Corporation plc (PRTA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support